| Prescribed dietary phosphate restriction and survival among hemodialysis patients. | |
| | |
MedLine Citation:
|
PMID: 21148246 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVES: Hyperphosphatemia is common among hemodialysis patients. Although prescribed dietary phosphate restriction is a recommended therapy, little is known about the long-term effects on survival. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a post hoc analysis of data from the Hemodialysis Study (n = 1751). Prescribed dietary phosphate was recorded at baseline and annually thereafter. Marginal structural proportional hazard models were fit to estimate the adjusted association between dietary phosphate restriction and mortality in the setting of time-dependent confounding. RESULTS: At baseline, prescribed daily phosphate was restricted to levels ≤ 870, 871 to 999, 1000, 1001 to 2000 mg, and not restricted in 300, 314, 307, 297, and 533 participants, respectively. More restrictive prescribed dietary phosphate was associated with poorer indices of nutritional status on baseline analyses and a persistently greater need for nutritional supplementation but not longitudinal changes in caloric or protein intake. On marginal structural analysis, there was a stepwise trend toward greater survival with more liberal phosphate prescription, which reached statistical significance among subjects prescribed 1001 to 2000 mg/d and those with no specified phosphate restriction: hazard ratios (95% CIs) 0.73 (0.54 to 0.97) and 0.71 (0.55 to 0.92), respectively. Subgroup analysis suggested a more pronounced survival benefit of liberal dietary phosphate prescription among nonblacks, participants without hyperphosphatemia, and those not receiving activated vitamin D. CONCLUSIONS: Prescribed dietary phosphate restriction is not associated with improved survival among prevalent hemodialysis patients, and increased level of restriction may be associated with greater mortality particularly in some subgroups. |
| | |
Authors:
|
Katherine E Lynch; Rebecca Lynch; Gary C Curhan; Steven M Brunelli |
Related Documents
:
|
15732576 - In vivo detoxification of fusarium toxins. 1564726 - A cholesterol reduction demonstration project: results from a challenge between two cit... 22460246 - Influence of genetic variants in the apolipoprotein a5 and c3 gene on lipids, lipoprote... 1629886 - Measurement of capillary cholesterol as an aid to the management of hypertensive patien... 16186066 - Beneficial effects of atorvastatin on sd ldl and ldl phenotype b in statin-naive patien... 8985666 - The effects of a duplication in the ovine growth hormone (gh) gene on gh expression in ... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-12-09 |
Journal Detail:
|
Title: Clinical journal of the American Society of Nephrology : CJASN Volume: 6 ISSN: 1555-905X ISO Abbreviation: Clin J Am Soc Nephrol Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-03-17 Completed Date: 2011-06-30 Revised Date: 2012-03-01 |
Medline Journal Info:
|
Nlm Unique ID: 101271570 Medline TA: Clin J Am Soc Nephrol Country: United States |
Other Details:
|
Languages: eng Pagination: 620-9 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Chi-Square Distribution Female Humans Hyperphosphatemia / diet therapy*, etiology, mortality Kaplan-Meier Estimate Linear Models Logistic Models Male Middle Aged Nutritional Status Phosphates / administration & dosage, adverse effects* Phosphorus, Dietary / administration & dosage, adverse effects* Proportional Hazards Models Prospective Studies Renal Dialysis / adverse effects, mortality* Risk Assessment Risk Factors Survival Rate Time Factors Treatment Outcome United States / epidemiology |
| Grant Support | |
ID/Acronym/Agency:
|
DK079056/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Phosphates; 0/Phosphorus, Dietary |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: LC3A autophagic acivity and prognostic significance in non-small cell lung carcinomas.
Next Document: Dialysis at a Crossroads: 50 Years Later.